Although studies with an androgen receptor (AR) suggest that before ligand binding the receptor is located in the cytoplasm, that may in fact be a nucleus like downregulation of ERβ mRNA expression in hormone-refractory tumors, which provokes the acquisition of mesenchymal characteristics and aggressive behavior of the PCa cells (3) which could influence clinical symptomatic cancer and the initiation of PCa. The gene discussed is AR; the disease is posterior cortical atrophy.